- Home
- KEN vs BEAM Comparison
KEN vs BEAM Comparison
Compare KEN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- BEAM
- Stock Information
- Founded
- KEN 2014
- BEAM 2017
- Country
- KEN Singapore
- BEAM United States
- Employees
- KEN N/A
- BEAM N/A
- Industry
- KEN Electric Utilities: Central
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KEN Utilities
- BEAM Health Care
- Exchange
- KEN Nasdaq
- BEAM Nasdaq
- Market Cap
- KEN 1.8B
- BEAM 1.6B
- IPO Year
- KEN N/A
- BEAM 2020
- Fundamental
- Price
- KEN $37.25
- BEAM $17.39
- Analyst Decision
- KEN
- BEAM Strong Buy
- Analyst Count
- KEN 0
- BEAM 11
- Target Price
- KEN N/A
- BEAM $48.90
- AVG Volume (30 Days)
- KEN 16.8K
- BEAM 1.7M
- Earning Date
- KEN 05-28-2025
- BEAM 08-05-2025
- Dividend Yield
- KEN 13.30%
- BEAM N/A
- EPS Growth
- KEN N/A
- BEAM N/A
- EPS
- KEN 11.35
- BEAM N/A
- Revenue
- KEN $760,304,000.00
- BEAM $63,578,000.00
- Revenue This Year
- KEN N/A
- BEAM N/A
- Revenue Next Year
- KEN N/A
- BEAM $10.03
- P/E Ratio
- KEN $3.16
- BEAM N/A
- Revenue Growth
- KEN 5.78
- BEAM N/A
- 52 Week Low
- KEN $23.31
- BEAM $13.53
- 52 Week High
- KEN $37.50
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- KEN 65.81
- BEAM 41.55
- Support Level
- KEN $34.52
- BEAM $16.38
- Resistance Level
- KEN $36.60
- BEAM $18.33
- Average True Range (ATR)
- KEN 0.58
- BEAM 1.04
- MACD
- KEN -0.07
- BEAM -0.02
- Stochastic Oscillator
- KEN 89.60
- BEAM 26.83
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.